Loading
The retinoid X receptor is a switch inside cells that vitamin A-like molecules turn on to change which genes are active; bexarotene uses it to make lymphoma cells in the skin mature and die. This dossier gathers the 3 products (3 approved), 5 trials, 2 pathways and 0 resistance routes in the corpus that involve it, with external identifiers so it can be joined to UniProt, ChEMBL, Open Targets and the rest of biology.
Ligand binding recruits co-activators and drives differentiation and apoptosis genes in malignant T cells; RXR also modulates PPAR-gamma-dependent lipid metabolism.
| Cancer | Prevalence | Measure | Note | Source |
|---|---|---|---|---|
| Metastatic cancer | all% | Signalling protein present in most cells (retinoid X receptor); bexarotene acts on the pathway rather than on a mutation that selects patients, so no prevalence applies. |
Approximate, population-level figures; the measure column says what was counted. Ranges show the midpoint as a bar.
| Modality | Approved |
|---|---|
| Small molecule 3 |
| Trial | Setting | Result | Products | ||
|---|---|---|---|---|---|
COG ACNS0332 NCT00392327 | 3 | Mixed | Newly diagnosed high-risk medulloblastoma in children aged 3 to 21: craniospinal radiotherapy with weekly vincristine, with or without daily carboplatin, and with or without isotretinoin maintenance | Carboplatin radiosensitisation improved event-free and overall survival in group 3 high-risk medulloblastoma; isotretinoin maintenance was stopped for futility. | |
ANBL0531 NCT00499616 | 3 | Positive | Intermediate-risk neuroblastoma: response- and biology-based assignment to two, four or eight cycles of carboplatin, etoposide, cyclophosphamide and doxorubicin (with topotecan for poor responders) and surgery, with isotretinoin for the highest-risk subset and no chemotherapy for some stage 4S infants | Three-year event-free survival 83.2 percent and overall survival 94.9 percent with response- and biology-based reduction of chemotherapy; overall survival 100 percent for localised disease. | |
ALCANZA NCT01578499 | 3 | Positive | Previously treated CD30-positive cutaneous T-cell lymphoma (mycosis fungoides or primary cutaneous anaplastic large cell lymphoma): brentuximab vedotin against physician's choice of methotrexate or bexarotene | Brentuximab vedotin produced far more objective responses lasting at least four months than methotrexate or bexarotene; approved in November 2017. | |
COG ANBL0032 NCT00026312 | 3 | Positive | High-risk neuroblastoma after transplant: ch14.18 (dinutuximab) + GM-CSF + IL-2 + isotretinoin vs isotretinoin alone | 2-year EFS 66% vs 46%; OS 86% vs 75%. | |
| 2 | - | A Phase II Study of Vemurafenib Combined With Acitretin in Patients With Advanced Melanoma | - |
No recorded escape route names this target.
KEGG's AML map shows the two hits that turn a normal blood stem cell into a leukaemia: a growth signal jammed on (FLT3, KIT or RAS) plus a broken maturation switch (fusion proteins such as PML-RARA or AML1-ETO, or mutated CEBPA and RUNX1). Drugs now exist for both halves.
Which nodes have drugs →KEGG's small cell lung cancer map shows a tumour with both master brakes removed, RB1 and TP53, plus amplified MYC pushing the cell cycle and PTEN loss and BCL2 keeping cells alive. Chemotherapy with PD-L1 antibodies and the DLL3 T-cell engager tarlatamab are the current answers.
Which nodes have drugs →No companion diagnostic in the registry measures this target.
No model entry for this target yet; check the cancer entries on the models page.
No open questions recorded for this target yet. Suggest one.
Query for this target: (TITLE:"Retinoid X receptor" OR ABSTRACT:"Retinoid X receptor" OR TITLE:"RXR" OR ABSTRACT:"RXR" OR TITLE:"RXRA" OR ABSTRACT:"RXRA" OR TITLE:"RXRB" OR ABSTRACT:"RXRB" OR TITLE:"RXRG" OR ABSTRACT:"RXRG") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Retinoid X receptor (RXR), not a curated reading list.
The dossier as machine-readable JSON, at /api/v1/dossiers/rxr.json: identifiers from HGNC, Ensembl, UniProt and ChEMBL, products with status, trials, pathways, hotspots, open questions and assays. The full entity record is in the open API at /api/v1/entities/rxr.json. Licence CC BY-NC 4.0.